HAS Healthcare Advanced Synthesis Strengthens Global Leadership with Cerbios-Pharma Acquisition

Deal News | Mar 31, 2025 | PR Newswire Cision 65 Equity Partners; HAS Healthcare Advanced Synthesis

HAS Healthcare Advanced Synthesis SA has announced the acquisition of Cerbios-Pharma SA to form a leading force in the Contract Development and Manufacturing Organization (CDMO) sector, with the backing of 65 Equity Partners. This merger combines their strengths in production, chemical, and biological expertise to create new growth opportunities while establishing an international leadership position. The acquisition process is contingent on regulatory and tax approvals and is supported by 65 Equity Partners, becoming a 40% shareholder alongside the Braglia family. This move is seen as catalyzing an international chemical-pharmaceutical hub in Ticino, Switzerland. Both HAS and Cerbios bring extensive expertise in APIs, complex therapies, and high-potency compounds to meet global pharmaceutical demands. The strategic backing of 65 Equity Partners aims to drive innovation and long-term growth within Switzerland's Ticino region, preserving each company's strong corporate culture and family ownership values.

Sectors

  • Pharmaceuticals
  • Contract Development and Manufacturing Organization (CDMO)
  • Private Equity

Geography

  • Switzerland – Both HAS and Cerbios are based in Switzerland, and the acquisition aims to strengthen the pharmaceutical industry in the Ticino region.
  • Europe – 65 Equity Partners operates in Europe and is involved in investing in this European-based transaction.

Industry

  • Pharmaceuticals – The acquisition involves companies specialized in active pharmaceutical ingredients and drug manufacturing.
  • Contract Development and Manufacturing Organization (CDMO) – Both HAS Healthcare Advanced Synthesis and Cerbios-Pharma operate within the CDMO sector, providing development and manufacturing services to the pharmaceutical industry.
  • Private Equity – 65 Equity Partners, a private equity firm, is backing the merger financially, showcasing its investment strategy in the healthcare sector.

Financials

  • c.40% – 65 Equity Partners becomes a 40% shareholder in the new entity formed by the acquisition.
  • US$3.3 billion – Total funds under management by 65 Equity Partners.

Participants

NameRoleTypeDescription
HAS Healthcare Advanced Synthesis SAAcquirerCompanyA developer and producer of active pharmaceutical ingredients and anticancer compounds based in Switzerland.
Cerbios-Pharma SATargetCompanyA manufacturer of chemical and biological APIs, including antibody drug conjugates.
65 Equity PartnersPrivate Equity FirmCompanyA global investment firm supporting the acquisition, becoming a 40% shareholder.
Braglia FamilyOwnerPeopleFamily owners of HAS Healthcare Advanced Synthesis SA.
Riccardo BragliaCEO & Board MemberPeopleCEO of 3B Future Holding SA and Board Member of HAS Healthcare Advanced Synthesis SA.
Pascal HeberlingPartner and Co-Head of EuropePeoplePartner at 65 Equity Partners.
Waldo MossiCEOPeopleCEO of HAS Healthcare Advanced Synthesis SA.
Christian SuàCEOPeopleCEO of Cerbios-Pharma SA.